Semaglutide injection (Wegovy™) for weight loss in obesity and overweight

Semaglutide injection (Wegovy™) is a glucagon-like peptide-1 (GLP-1) receptor agonist that is given as a once-weekly subcutaneous injection for “chronic weight management” in specified subgroups of patients (see FDA indications below). It was approved by the FDA in 2021 and was the first weight-loss medication to be approved since 2014. Whom is it for? The…